0G85 Stock Chart & Stats
kr1.82
kr0.00(0.00%)
At close: 4:00 PM EDT
kr1.82
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr1.82 - kr1.82
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
kr308.00M
Enterprise Valuekr268.87
Total Cash (Recent Filing)kr43.09M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding394,878,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr41.00M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthA return to double-digit trailing revenue growth indicates improving commercial traction and customer adoption. If sustained, this can support operating leverage and strengthen the installed base that drives future hospital and consumables revenue.
Debt-Free Balance SheetThe absence of debt materially limits interest burden, refinancing exposure, and lender restrictions. The substantial equity base provides financial flexibility to fund commercialization and product development, although continued losses could erode this advantage.
Recurring Consumables Business ModelA hospital-installed device base can create recurring single-use consumables and service revenue beyond the initial equipment sale. This razor-and-blades model may improve customer retention and revenue visibility as clinical utilization expands.
Bears Say
Persistent UnprofitabilityNegative gross profit and sustained operating and net losses indicate that the current commercial model has not yet achieved economic scalability. Without material margin improvement, revenue growth may continue to require external funding rather than generate shareholder value.
Heavy Cash BurnCash losses of this magnitude show that reported losses are translating into real funding needs. Persistent burn can constrain investment capacity and increase reliance on future capital raising, even with no current debt on the balance sheet.
Negative Returns And Equity Dilution RiskNegative returns indicate that the equity base is not currently producing economic returns. If losses persist, management may need additional financing, creating a durable risk of equity erosion or dilution despite the company’s conservative leverage profile.
BrainCool AB News
0G85 FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest share price was kr1.82 and its highest was kr1.82 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is kr308.00M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Nov 11, 2026 which is in 74 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on Aug 12, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate is 0.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in GB:0G85
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company caters to the healthcare sector, primarily serving the Swedish market, by providing innovative solutions for various conditions including stroke, sudden cardiac arrest, oral mucositis, and migraine. Their product line features the BrainCool and RhinoChill systems, specifically engineered to deliver swift therapeutic cooling in emergency situations, thereby ensuring uninterrupted patient care. To mitigate the risk of oral mucositis, BrainCool offers the Cooral system, renowned for its user-friendly design for medical professionals. Furthermore, the IQool system boasts an intuitive interface complemented by informative graphics and an automatic feedback loop, empowering clinicians to dedicate their attention to patient management rather than device operation.